ABCL earnings: real EPS beat/miss history, analyst consensus Buy, P/E -11.94. Updated 2026-07-23.
AbCellera Biologics (ABCL) Research Hub
AbCellera Biologics (ABCL) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 10.89 USD (-1.45%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -11.94, market cap 1.79B. This hub links to the full technical, earnings and options research available for ABCL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CA |
| Last close | 10.89 USD (-1.45%) |
| 52-week range | 4.98 USD – 12.5 USD |
| Trend regime | Range |
| 14-day RSI | 71.6 (Overbought) |
| Trailing P/E | -11.94 |
| Market cap | 1.79B |
| Dividend yield | 0.00% |
Available research for ABCL
Covered Call on ABCL: how it works, illustrative setup around the real 10.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ABCL: how it works, illustrative setup around the real 10.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ABCL: how it works, illustrative setup around the real 10.89 USD price, max profit/loss, breakeven and when to use it. Educational.
ABCL technical analysis: range, last 10.89 USD, RSI 71.6, 52w range 4.98 USD–12.5 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ABCL in?
AbCellera Biologics (ABCL) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.
Is ABCL in an uptrend or downtrend?
As of 2026-09-11, ABCL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ABCL's trailing P/E ratio?
ABCL's trailing P/E is -11.94, with a market cap of 1.79B. See the earnings research page for full valuation detail.